Fast facts: multiple sclerosis (Journal of Neurology, Neurosurgery, and Psychiatry)

It is an exciting time to be involved in the treatment of multiple sclerosis (MS). While the exact cause still remains elusive, over the last decade there have been a plethora of new treatments and approaches: disease modifying and symptomatic. This third edition therefore comes at exactly the right time and reflects the dynamic nature of the field, with plenty for healthcare professionals of all backgrounds. A brief tour of the contents page gives a flavour with, for example, chapters on pathology, clinical presentation, relapse modification, special situations such as pregnancy and of course vitally, the multidisciplinary team. Considering the symptom management section there are well-described pieces on fatigue management (eg, the FACETS programme), baclofen pumps, intravesical botulinum toxin and functional electrical stimulation. Central is the status of disease modification in the relapsing–remitting phase, and the new oral (eg, fingolimod) and monoclonal antibody approaches (eg, natalizumab and alemtuzumab) are...